{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:23:15Z","timestamp":1783650195989,"version":"3.55.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"publisher","award":["Z-2014-08-2309-5"],"award-info":[{"award-number":["Z-2014-08-2309-5"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ustekinumab, approved in 2016 for the treatment of Crohn's disease (CD), its safety profile remains insufficiently characterized in real-world settings. This study aims to enhance clinical safety by identifying adverse events (AEs) associated with ustekinumab through data mining of the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>AEs data for ustekinumab in CD treatment were extracted from the FAERS database. Duplicate and incomplete reports were excluded during preprocessing. Signal detection was performed using the reported odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayesian geometric mean (EBGM), with established thresholds applied for signal identification. AEs were classified based on the system organclass (SOC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 17,187 AEs associated with ustekinumab in CD were identified, generating 44,232 signals across 24 SOCs and 258 preferred terms (PTs). The most frequent reports were categorized under \u201cinjury, poisoning, and procedural complications,\u201d while \u201cinfections and infestations\u201d emerged as one of the most frequently reported SOCs. Statistically significant PTs included abscess (ROR = 25.36, 95% CI: 22.51\u201328.58), clostridium difficile infection (ROR = 14.37, 95% CI: 12.72\u201316.24), and lower respiratory tract infection (ROR = 13.54, 95% CI: 12.37\u201314.83). Notable signals were also identified for hepatobiliary disorders (2.24% mortality) and cardiac disorders (7.50% mortality, the highest among all SOCs). Rare events, such as congenital pulmonary airway malformation, were observed; however, these findings were limited to a small number of cases and warrant cautious interpretation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In the treatment of CD with ustekinumab, it is critical to monitor not only common AEs like infections and tumors, but also less frequent yet severe AEs, including cardiac disorders, hepatobiliary disorders, and possible congenital anomalies. The latter, however, requires further validation through additional clinical evidence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1657247","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T06:22:46Z","timestamp":1762410166000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Adverse events associated with ustekinumab in Crohn's disease treatment: an analysis based on the FAERS database"],"prefix":"10.3389","volume":"12","author":[{"given":"Chiwei","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/ecco-jcc\/jjab029","article-title":"The burden of inflammatory bowel disease in Europe in 2020","volume":"15","author":"Zhao","year":"2021","journal-title":"J Crohns Colitis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s12325-023-02473-6","article-title":"Epidemiological, clinical, patient-reported and economic burden of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in Spain: a systematic review","volume":"40","author":"Barreiro-de Acosta","year":"2023","journal-title":"Adv Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"goae053","DOI":"10.1093\/gastro\/goae053","article-title":"Global patterns in the epidemiology, cancer risk, and surgical implications of inflammatory bowel disease","volume":"12","author":"Zhang","year":"2024","journal-title":"Gastroenterol Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn's disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"MAbs."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1080\/14712598.2025.2556909","article-title":"Long-term effectiveness and safety of ustekinumab in patients with Crohn's disease: real-world evidence","volume":"25","author":"Wu","year":"2025","journal-title":"Expert Opin Biol Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s43440-025-00774-x","article-title":"Real-world safety and efficacy of biological agents in inflammatory bowel disease: a one-year post-marketing pharmacovigilance observational study in the Calabria region","volume":"77","author":"Fabiano","year":"2025","journal-title":"Pharmacol Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.5217\/ir.2022.00029","article-title":"Korean clinical practice guidelines on biologics for moderate to severe Crohn's disease","volume":"21","author":"Koh","year":"2023","journal-title":"Intest Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1322319","DOI":"10.3389\/fphar.2023.1322319","article-title":"A bibliometric and visual analysis of the use of ustekinumab in Crohn's disease using CiteSpace","volume":"14","author":"Chen","year":"2023","journal-title":"Front Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7150\/ijms.7967","article-title":"Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms","volume":"11","author":"Sakaeda","year":"2014","journal-title":"Int J Med Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s40264-018-0706-7","article-title":"A critical evaluation of safety signal analysis using algorithmic standardised MedDRA queries","volume":"41","author":"Tieu","year":"2018","journal-title":"Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"Dumouchel","year":"1999","journal-title":"Am Stat."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000003421","article-title":"Antiplatelet therapy and central nervous system hematomas: a cohort study using real-world data from the FAERS and vigiaccess databases","author":"Wang","year":"2025","journal-title":"Int J Surg."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673378809250707043350","article-title":"Post-marketing safety surveillance of drug-induced dementia: utilizing signal detection and Mendelian randomization in spontaneous reports","author":"Chen","year":"2025","journal-title":"Curr Med Chem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s10620-021-06932-4","article-title":"Effectiveness and safety of ustekinumab in inflammatory bowel disease: a systematic review and meta-analysis","volume":"67","author":"Honap","year":"2022","journal-title":"Dig Dis Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1111\/apt.16119","article-title":"Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy","volume":"52","author":"Panaccione","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00384-024-04636-5","article-title":"Trends in the prevalence and incidence of Crohn's disease in Japan and the United States","volume":"39","author":"Nakajo","year":"2024","journal-title":"Int J Colorectal Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1371322","DOI":"10.3389\/fped.2024.1371322","article-title":"Ustekinumab in pediatric patients with Crohn's disease: safety, and efficacy results from a multicenter retrospective study in China","volume":"12","author":"Li","year":"2024","journal-title":"Front Pediatr."},{"key":"B26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4103\/sjg.sjg_7_24","article-title":"Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: a retrospective cohort study","volume":"31","author":"Alhadab","year":"2025","journal-title":"Saudi J Gastroenterol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s12664-023-01391-3","article-title":"Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn's disease","volume":"42","author":"Garg","year":"2023","journal-title":"Indian J Gastroenterol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-09395-z","article-title":"Safety and efficacy of ustekinumab and vedolizumab among older adults with inflammatory bowel disease","author":"Sachar","year":"2025","journal-title":"Dig Dis Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"102107","DOI":"10.1016\/j.clinre.2023.102107","article-title":"Risk of infection in elderly patients with inflammatory bowel disease under biologics: a prospective, multicenter, observational, one-year follow-up comparative study","volume":"47","author":"Bozon","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.cgh.2022.06.030","article-title":"Global hospitalization trends for Crohn's disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses","volume":"21","author":"Buie","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1159\/000530107","article-title":"Association of nonmelanoma skin cancers, melanoma, and merkel cell carcinoma with dermatologic medications: a case-control pharmacovigilance study of the FDA adverse events reporting system","volume":"239","author":"Jedlowski","year":"2023","journal-title":"Dermatology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40264-019-00797-3","article-title":"Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn's disease: an integrated analysis of phase II\/III clinical development programs","volume":"42","author":"Ghosh","year":"2019","journal-title":"Drug Saf."},{"key":"B33","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1093\/ibd\/izaa236","article-title":"Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2\/3 studies","volume":"27","author":"Sandborn","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in Crohn's disease: the IM-UNITI trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/apt.15784","article-title":"Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy","volume":"52","author":"Kopylov","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.14309\/ajg.0000000000002047","article-title":"The real-world effectiveness and safety of ustekinumab in the treatment of Crohn's disease: results from the SUCCESS consortium","volume":"118","author":"Johnson","year":"2023","journal-title":"Am J Gastroenterol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"14248","DOI":"10.1038\/s41598-024-65129-7","article-title":"Chemotherapy-induced high expression of IL23A enhances efficacy of anti-PD-1 therapy in TNBC by co-activating the PI3K-AKT signaling pathway of CTLs","volume":"14","author":"Pan","year":"2024","journal-title":"Sci Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3892\/ol.2012.739","article-title":"IL-23 directly enhances the proliferative and invasive activities of colorectal carcinoma","volume":"4","author":"Suzuki","year":"2012","journal-title":"Oncol Lett."},{"key":"B39","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/exd.13676","article-title":"Inhibition of interleukin-12 and\/or interleukin-23 for the treatment of psoriasis: what is the evidence for an effect on malignancy?","volume":"27","author":"Ergen","year":"2018","journal-title":"Exp Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"950","DOI":"10.4049\/jimmunol.1601455","article-title":"IL-23 Inhibits melanoma development by augmenting DNA repair and modulating T cell subpopulations","volume":"198","author":"Nasti","year":"2017","journal-title":"J Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/ecco-jcc\/jjy153","article-title":"Drug levels in the maternal serum, cord blood and breast milk of a ustekinumab-treated patient with Crohn's disease","volume":"13","author":"Klenske","year":"2019","journal-title":"J Crohns Colitis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12876-017-0633-6","article-title":"Fetal death in utero and miscarriage in a patient with Crohn's disease under therapy with ustekinumab: case-report and review of the literature","volume":"17","author":"Venturin","year":"2017","journal-title":"BMC Gastroenterol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1093\/ecco-jcc\/jjac086","article-title":"Safety of ustekinumab and vedolizumab during pregnancy-pregnancy, neonatal, and infant outcome: a prospective multicentre study","volume":"16","author":"Mitrova","year":"2022","journal-title":"J Crohns Colitis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.cgh.2024.01.008","article-title":"Infant ustekinumab clearance, risk of infection, and development after exposure during pregnancy","volume":"23","author":"Julsgaard","year":"2025","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.cgh.2023.12.029","article-title":"Safety of vedolizumab and ustekinumab compared with anti-TNF in pregnant women with inflammatory bowel disease","volume":"23","author":"Meyer","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1007\/s10620-024-08421-w","article-title":"Correlation between serum and fecal biomarkers and patient-reported outcomes in patients with Crohn's disease and ulcerative colitis","volume":"69","author":"Motwani","year":"2024","journal-title":"Dig Dis Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cgh.2020.02.035","article-title":"Effectiveness of ustekinumab dose escalation in patients with Crohn's disease","volume":"19","author":"Ollech","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"17562848231153560","DOI":"10.1177\/17562848231153560","article-title":"Effectiveness and safety of ustekinumab in bio-na\u00efve Crohn's disease patients: a multicentre observational retrospective study","volume":"16","author":"Teresa","year":"2023","journal-title":"Therap Adv Gastroenterol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1136\/dtb.2023.250376rep","article-title":"Heart failure associated with ustekinumab therapy for treatment of Crohn's Disease","volume":"61","author":"Morgenweck","year":"2023","journal-title":"Drug Ther Bull."},{"key":"B50","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/17474124.2023.2194631","article-title":"Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Shehab","year":"2023","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/eurheartj\/ehs263","article-title":"Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction","volume":"34","author":"Simon","year":"2013","journal-title":"Eur Heart J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/ni.2001","article-title":"The immune system in atherosclerosis","volume":"12","author":"Hansson","year":"2011","journal-title":"Nat Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"196ra100","DOI":"10.1126\/scitranslmed.3006133","article-title":"Transforming growth factor-\u03b2 signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway","volume":"5","author":"Gister\u00e5","year":"2013","journal-title":"Sci Transl Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.biopha.2018.07.110","article-title":"The pleiotropic role of interleukin-17 in atherosclerosis","volume":"106","author":"Allam","year":"2018","journal-title":"Biomed Pharmacother."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1001\/jamadermatol.2020.2977","article-title":"Association between early severe cardiovascular events and the initiation of treatment with the anti-interleukin 12\/23p40 antibody ustekinumab","volume":"156","author":"Poizeau","year":"2020","journal-title":"JAMA Dermatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1494283","DOI":"10.3389\/fimmu.2025.1494283","article-title":"Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents","volume":"16","author":"Picchianti-Diamanti","year":"2025","journal-title":"Front Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/MEG.0000000000002076","article-title":"Review article: safety of new biologic agents for inflammatory bowel disease in the liver","volume":"33","author":"Magr\u00ec","year":"2021","journal-title":"Eur J Gastroenterol Hepatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1657247\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:36:43Z","timestamp":1762429003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1657247\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":57,"alternative-id":["10.3389\/fmed.2025.1657247"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1657247","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"article-number":"1657247"}}